Annual Report for 2012 on Form 20-F filed with the SEC on April 5, 2013
BARCELONA, Spain, April 5, 2013
BARCELONA, Spain, April 5, 2013 /PRNewswire/ -- Grifols, S.A. ("Grifols")
(MCE:GRF, MCE:GRF.P and NASDAQ: GRFS), announced that it has filed its 2012
Annual Report on Form 20-F with the United States Securities and Exchange
Commission ("SEC") on April 5, 2013. Grifols' Annual Report on Form 20-F
includes its audited financial statements for its fiscal year ended December
Form 20-F can be accessed electronically through the Grifols website at
http://inversores.grifols.com/portal/es/grifols/sec_filings. The Form 20-F is
also available on the SEC's website at http://www.sec.gov.
Grifols will deliver, within a reasonable time after request, a hard copy of
the Form 20-F, including its complete audited financial statements, free of
charge, to any shareholder upon request. To request a hard copy, shareholders
may contact Grifols by email at firstname.lastname@example.org to the attention of
Grifols's Investor Relations, Re: 2012 Annual Report on Form 20-F.
Grifols is a global healthcare company with a 70-year legacy of improving
people's health and well being through the development of life-saving plasma
medicines, hospital pharmacy products and diagnostic technology for clinical
As the third largest global producer of plasma medicines, Grifols has a
presence in more than 100 countries and is the world leader in plasma
collection, with 150 plasma donation centers across the U.S. Grifols is
committed to increasing patient access to its life-saving plasma medicines
through significant manufacturing expansions and the development of new
therapeutic applications of plasma proteins. The company is headquartered in
Barcelona, Spain and employs more than 11,000 people worldwide.
In 2012, Grifols' sales exceeded 2,620 million euros. The company's class A
shares are listed on the Spanish Stock Exchange, where they are part of the
Ibex-35 (MCE:GRF). Its non-voting class B shares are listed on the Mercado
Continuo (MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more
information visit www.grifols.com
Contact: GRIFOLS Investor Relations, E-mail: email@example.com Tel: + 34
93 571 0221 Fax: + 34 93 571 2201
Press spacebar to pause and continue. Press esc to stop.